Member Info for Diplomat65

Made in Chiii-naaah . . .

Your Monica says it all - lol.

Pay a subscription and you can access Level 2 share data.

The treatment the president received is an antibody ****tail developed by the biotech company Regeneron, according to the memo from his doctor, Sean P. Conley. Mr. Trump is also taking vitamin D, zinc, melatonin, a daily aspirin and famotidine (an antacid better known as Pepcid), the memo said.

Initial results suggest that Regeneron’s treatment can lower the level of the virus in the body when administered early in the course of an infection.
Daewoong should get on the phone and offer him a shot of AffyXell.

I would appreciate thoughts from the scientists’ on here about this claim
https://youtu.be/06yja21V7xg

Lostinspace69 asks:
“ Is the problem here that we backed the wrong horse with CONDOR? If it's a technical hurdle that's the issue, then how come Abbott and Roche and others have managed to leapfrog Avacta and successfully launch their rapid Antigen tests?”
Am I right to understand AVCT had to work through/with Condor because our LFD will be used in the home with no professional/clinical input prior to the result being known and accepted outside the home?

https://messageboardfools.com/bashers.htm

Courtesy of UK2Day over on ADVFN I found this to be an entertaining and informative read deserving of 10 minutes of your time if interested in the motivations of irritants such as AW and One-post wonders like Oh No etc.
htTps://messageboardfools.com/bashers.htm

Whenever the LFD is ready to ship, one irrefutable fact remains clear: demand for our test continues to grow. The global death toll passed 980,000 on Friday, according to the Johns Hopkins University tracker. With the number of deaths confirmed daily averaging more than 5,000, it looks likely the toll will pass 1 million within days. There are 32m cases worldwide. How much pressure do you imagine everyone at AVCT is feeling to see their test approved, manufactured and released in the face of these horrendous numbers? They certainly don’t need additional pressure from PI’s banging their door down demanding to know the time lines. They know what is at stake: saving lives, not bloating PI’s pension funds.

Yes . . . . the lateral flow antigen test -
“ Testing technology listed in the documents includes qrt-PCR, Endpoint PCR, LAMP, LamPORE, lateral flow antigen test, and whole genome sequencing. Two of these tests—lateral flow antigen tests and LAMP—are listed as having a “lower sensitivity” of between 80% and 100%.”

Thanks RD - I sold some slow movers in my SIPP and moved the proceeds into AVCT. I'll be drawing down in the coming years. Thanks AfamaMan, my ISA is loaded too. RK - I just don't see a better "bet" than AVCT right now and am excited about the pre|Cision opportunity for 2021 too.

Decided to take full advantage of this artificially low price and moved the bulk of my SIPP into AVCT at an average of £1.58. Now holding over 120,000 of these golden tickets and looking forward to the inevitable rise. Patience is key here and I see myself as a very patient LTH. GLA.

This sentence referring to “clinical study” is disappointing:
“ The Group’s immediate focus nevertheless remains on its prospectively global-scale opportunity for a saliva-based coronavirus antigen rapid test that is being developing with Cytiva, which is now in the process of technology transfer to its manufacturing partners. A first pilot batch could possibly be available later this month to begin the clinical study.”

I have sent Avacta a copy of this exchange of emails I had with Medusa19’s sales team on Tuesday. I asked if I could place an advance order for Avacta’s LFD and received the following misleading information from them:
“ -----Original Message-----
Sent: 02 September 2020 10:39
To: sales
Subject: Avacta LFD
Good morning,
Can I place an advanced order now please?

Medusa19's reply:
On 2 Sep 2020, at 10:55, sales wrote:
Good morning XXXX
I have attached an 'expression of interest' form for you to complete. Once you return to me with confirmation of how many units you need (minimum order 50, then multiples of 50 thereafter), I will send you our bank transfer details.
Once you confirm payment, I will get in touch with you once the funds clear and arrange for delivery which is estimated within 4 weeks at the moment.
Regards
XXXX
Head of Customer Service/Delivery
From: Me
Sent: 02 September 2020 11:12
To: sales
Subject: Re: Avacta LFD

Thanks.
How much are the 50 unit's please? I'd like to know before setting up bank info, thank you.

From Medusa19
Sent: 02 September 2020 11:18
To: Me
Subject: RE: Avacta LFD

Hi XXXX

Prices for each unit is £40 or 45 euros x 50 and delivery costs are dependent on which country we are delivering to - for example I have just done a quote to Spain which worked out at:

Price will be 45 euro per test x minimum order of 50 units = 2250 euro + 20 euro delivery - no VAT (Europe only) if VAT number is supplied Total cost - 2270 euro.

I have attached some photos and a copy of our brochure for you to look at but anything else just let me know.
Regards
Head of Customer Service/Delivery
Website: www.medusa19.com

From: Me
Sent: 02 September 2020 11:24
To: XXXX@medusa19.com>
Subject: RE: Avacta LFD
Thanks XXXX
I believe this information relates to an antibody test.
I am only interested in the Avacta antigen LFD as indicated in my subject line.
How much will the Avacta test cost please? I am also a member of the public, this is not a commercial/corporate enquiry. Thank you for your patience!
Kind regards,

From: XXXX@medusa19.com>
Sent: 02 September 2020 11:27
To: Me
Subject: RE: Avacta LFD
Hi
We have no updates on the Avacta product for consumers, but as and when we get updates the website will also get updated. I will also keep you on file, if you don't mind and as soon as we hear anything I will get in touch
Regards”

He refers to a home-use, pregnancy style spit test being the most advanced but and I quote “. . . tricky to pull off. . .”
What is he referring to as “tricky” I wonder?

The Food and Drug Administration has granted emergency authorization to Abbott for a cheap, portable coronavirus test that gives results in 15 minutes, the company said on Wednesday.

The device is about the size of a credit card, and opens like a book to reveal a small well. A health practitioner takes a swab from the patient’s nostrils, adds a few drops of chemicals into the hole, inserts the swab directly into the card and rotates it.

The device, called the BinaxNOW Covid-19 Ag Card, works by rapidly detecting fragments of virus in a sample, a method known as an antigen test. But while such tests are faster than those that rely on a technology called polymerase chain reaction, or P.C.R., they tend to miss more infections.

BinaxNOW is the fourth coronavirus antigen test to win an emergency authorization from the F.D.A. Earlier this month, the agency cleared one made by LumiraDx, a British firm.
Abbott said its new test detected virus in 97.1 percent of people who have it, and accurately reported no virus in 98.5 percent of people who don’t.

In March, the F.D.A. approved another rapid test developed by Abbott that was later found to miss a significant number of infections.

The BinaxNOW test will come with a mobile app for iPhone and Android devices that updates each time a person retakes it.

In a statement, the company said it would begin shipping millions of tests in September, ramping up to 50 million a month beginning in early October.

The test will cost $5.

This article claims paper tests have low sensitivity which is why FDA are withholding EUA. I thought our LFD had very high (95%+) sensitivity so should not be be lumped in with these $1 tests.

“If a saliva sample has coronavirus present, the antibody will bind that viral antigen, turning the test positive, much like a pregnancy test works. Though the tests have much lower sensitivity than PCR tests overall, one advantage they have is that they do not detect leftover, inactive viral RNA particles, which may be present days to weeks after a person is infectious.”

I’ve emailed Sarah Hollins at Yellow Jersey PR and asked to edit this statement
“. . . a collaboration with LG Chem to develop treatments for autoimmune and inflammatory diseases worth up to $310m“

to read “over $400m”

I am a shareholder in both Avacta and IQE (https://www.iqep.com/ )
the UK’s global leader in advanced compound semiconductors.

One of IQE’s key customers is ams who are working with a German rapid test manufacturer linking results to smartphones and I wondered if this Innovation may be of interest to Avacta and our LFD? I received this press release from ams explaining the innovation:

COVID-19 virus test results in 15 minutes?

ams is providing the latest spectral sensor technology to medical technology startup, midge medical, to develop a disruptive technology for science-backed rapid genetic and blood testing in a home and professional healthcare environment.
midge medical’s current focus is on developing a pocket-sized COVID-19 (SARS-CoV-2) genetic test that enables test results to be read-out using a smartphone in as little as 15 minutes. It uses a specifically developed sensor system based on the ams AS7341L spectral sensor solution to allow spectrally resolved read out of amplified virus particles, strengthening ams’ position in delivering high-quality consumer health diagnostics.
This collaboration aims to provide a technology with the potential to move the current market forward.
?
https://ams.com/-/midge-medical

mstar: as you say, expect Medusa19 to expand their offering with other medical products as confirmed on their "About" web page
"Longer-term, the Group’s objective is to entrench itself within the global medical supply chain, serving businesses and consumers worldwide with a range of tests and solutions that identify a variety of conditions, supporting health, well-being and business continuity throughout the globe."

A small convenient stock of low-cost LFDs from Avacta (via Boohoo’s Mail order service) would be purchased and kept in the home until required providing instant results.